(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening in the third dosing cohort of its ongoing U.S. study of L-DOS47 in combination treatment with pemetrexed/carboplatin (“LDOS001”).
Helix-BioPharma-Corp.-Initiates-Third-Dosing-Cohort-July-25-2017.pdf